Edwards Q3 sales up 9% to $1.33B; TAVR +6%, TMTT +73%; adjusted EPS $0.67 beats guidance

Edwards Lifesciences Corp

2024-Q3 EPS reported $6.29 revenue$4,053,700,000

Q3 sales from continuing ops $1.33B (+9% as-reported, +10% constant currency); adjusted EPS $0.67 ahead of July guidance.
TAVR sales $1.0B (+6% reported, +7% constant currency); TMTT sales $91M (+73%) driven by PASCAL and EVOQUE launches.
GAAP EPS $5.13 includes one-time gain from sale of Critical Care unit; adjusted gross margin 80.7% vs 79.9% last year.
Repurchased $1.0B of stock in Q3; remaining authorization $1.4B; cash $3.5B, debt $600M.
Reiterated FY2024 total sales growth 8-10%; Q4 guidance: sales $1.33-1.39B, EPS $0.53-0.57.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.